

# Diagnosis and Management of Filler Adverse Effects: An Algorithm

Gabriele Feller-Heppt, MD<sup>1</sup> Eckart Haneke, MD, PhD<sup>2</sup> Markus V. Heppt, MD<sup>3</sup>

<sup>1</sup>Skin and Face Clinic, Baden-Baden, Germany

<sup>2</sup>Department of Dermatology, Inselspital, Universitätsspital Bern, Bern, Switzerland

<sup>3</sup>Department of Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germany

Address for correspondence Markus V. Heppt, MD, Department of Dermatology and Allergy, Ludwig-Maximilian University, Frauenlobstr. 9-11, 80337 Munich, Germany  
(e-mail: Markus.Heppt@med.uni-muenchen.de).

Facial Plast Surg 2014;30:647–655.

## Abstract

### Keywords

- injectable fillers
- side effects
- granuloma
- differential diagnosis
- treatment

Fillers are frequently used in beautifying procedures. Despite major advancements of the chemical and biological features of injected materials, filler-related adverse events may occur, and can substantially impact the clinical outcome. Filler granulomas become manifest as visible grains, nodules, or papules around the site of the primary injection. Early recognition and proper treatment of filler-related complications is important because effective treatment options are available. In this report, we provide a comprehensive overview of the differential diagnosis and diagnostics and develop an algorithm of successful therapy regimens.

After neurotoxins, fillers rank on the second place of beautifying procedures. It is an old wisdom that nothing with substantial efficacy does not—from time to time—cause adverse events as well. However, many side effects can be prevented obviating disappointment and ultimately litigation. Some fillers are more prone to cause adverse effects than others, but in principle, any injection, even of autologous material, introduces substances that are first recognized as foreign material. Sometimes, an objective measurement is necessary, which may require three-dimensional scanning.<sup>1</sup> The importance of an in-depth patient history cannot be overestimated and it is central to know whether other procedures have been performed at the same time or previously.<sup>2</sup> As most fillers are indeed predominantly injected into the facial area, an algorithm is given for this particular region. In this article, we present an algorithm for differential diagnosis, diagnostics, and treatment of frequent side effects of injectable fillers.

## Differential Diagnosis of Filler-Related Adverse Events

The most important visible filler side effects are swelling, bruising, necrosis, and ulceration.

Swellings are by far the most common and most diverse adverse effects. Important differential diagnoses are listed in ►Table 1. This table does not list congenital and other swellings that can easily be differentiated from filler-related complications, such as swellings in children or in the critically ill. The potential differential diagnoses responsible for facial swellings are numerous. It has to be kept in mind that some conditions, such as hereditary angioedema or Melkersson-Rosenthal syndrome can be provoked by the trauma of the injection procedure or by foreign bodies. Immunotherapy was also observed to induce granulomatous reactions to permanent fillers that had been well tolerated for many years. Fever is usually a sign of infection as in erysipelas and sometimes in abscesses, although “cold abscesses” do occur. Ultrasound did not substantially improve the differential diagnosis of solid swellings and cystic lesions such as abscesses. A skin rash may accompany the swelling. Overlying erythema may be a sign of a localized effect, whereas widespread skin lesions may point towards allergic reactions or a random association. An immediate onset is usually a sign of too much injected material, whereas appearance within a few hours or days may be due to allergic reaction. Granulomas and abscesses take many days to several weeks to develop clinically. In case the injected filler was a hyaluronan,

**Table 1** Differential diagnostic evaluation of facial swellings that may be related to filler injections

Swelling	
Family history of swellings and urticaria	Positive/negative
Atopy	Positive/negative
Medication	Yes/no <sup>25,26</sup>
Lymph node swelling	Yes/no
Previous injections	Yes/no <sup>27</sup>
Diffuse	
Onset	Acute/insidious
Event <sup>28</sup>	Single/recurrent
Fever	Yes/no
Skin rash	Yes/no <sup>29</sup>
Papules and pustules	Yes/no <sup>30</sup>
Previous surgery	Yes/no <sup>31</sup>
Localized	
Previous injections <sup>32</sup>	
Hematoma	
Constitutional symptoms	Yes/no <sup>33</sup>
Pain	Yes/no <sup>34</sup>
Paresis	Yes/no <sup>35</sup>
Orofacial granulomatosis (Melkersson–Rosenthal syndrome, <sup>36,37</sup> Crohn disease), oral mucosal lesions	Yes/no
Salivary gland infection	Yes/no
Abscess, infection <sup>38</sup>	
Arthropod assaults <sup>39</sup>	
Dental treatment	Yes/no <sup>40,41</sup>
Tumor, lymphoma	Yes/no <sup>42</sup>

hyaluronidase injection will correct the overdose within a few hours.

Bruising (► **Table 2**) is a common sequel of any injection, and short-lived minor bruises are not listed as a major adverse side effect. However, as soft tissue augmentation is often performed in middle-aged and elderly persons, intake of anticoagulants may be expected and has to be asked for. For a long time, they have been judged as a contraindication for intramuscular injections. It is therefore reasonable to assume that they may increase the risk of major bruises and even large hematomas. These may, in turn, give rise to infection, necroses, and ulceration. Bruises usually disappear within a few weeks depending on their size and localization. Typical is a color change and the swelling may migrate downwards following gravity. Whether or not evacuation of the hematoma is necessary depends on the amount of blood.

Necroses (► **Table 3**) may be due to inadvertent intravascular injection or pressure on blood vessels by the injected material.<sup>3</sup> Hyaluronic acid can be dissolved and degraded by

hyaluronidase, which should always be readily available in any practice injecting hyaluronans. It should be injected immediately into the area where the filler has been placed. It has not yet convincingly been proven if the intravenous hyaluronidase infusion is feasible and efficient.<sup>4</sup> It is advisable to use higher doses as these have a faster onset of action.<sup>5</sup> Surgical debridement should be done very cautiously as some of the discolored skin may still recover, particularly areas with epitheliolysis only.

Ulcerations (► **Table 4**) usually develop from preexistent necroses and their treatment depends on the underlying condition. For instance, if the ulceration is due to hyaluronan, injection of hyaluronidase is the treatment of choice.

Papules and nodules may occur immediately and represent just overfilling or are a sign of an uneven injection technique. Frequently, however, papules, nodules, and infiltrates are characteristic signs of chronic inflammatory processes, most commonly of a granuloma or abscess. They represent late complications, some of which may be allergic whereas most are due to chronic histiocyte/macrophage stimulation. In contrast to acute inflammatory conditions, they are usually not warm or inflamed. The history of their development is critical for the correct diagnosis. We would like to emphasize that these complications may occur after injection of any filler, both temporary as well as permanent, and probably without major differences in frequency. However, most of the nodules due to temporary fillers have a limited period of persistence.

## Diagnostics

Most patients seeking consultation for filler complication treatment received an external injection. Thus, taking a thorough and specific history is a central cue to the correct diagnosis.

Depending on the onset and the clinical appearance of filler side effects, several different diagnostic means are used. Whereas symptoms such as swelling, bruising or a certain sensation of pressure does not require therapy, a variety of local and systemic treatment options are available in case of moderate and severe complications. These include blood tests and microbiological examinations in case of suspected bacterial infection or if systemic reactions such as fever, headache, muscle pains, fatigue, and malaise are present.

Modern imaging methods and analyses improve the accuracy of differentiated topodiagnosis (► **Fig. 1**).<sup>6</sup> B-mode ultrasound examinations have their special value in the assessment of nodular formations in terms of abscess and lymph node diagnostics and in the therapeutic follow-up. Together with modern nuclear medicine, including white blood cell scintigraphy, high-resolution computed tomography, and magnetic resonance imaging, it is possible to differentiate between infection, granuloma formation, and fibrosis these days.<sup>6–12</sup> Despite these advancements in accurate imaging, the ultimate identification of certain filler substances—if not evident from the patient's history—require histopathological investigation (► **Fig. 2**), or optionally characterization by chromatography, mass spectrometry, or capillary electrophoresis.<sup>10</sup>

**Table 2** Differential diagnostic considerations of major bruising that may be related to filler injections

Major bruising	
Family history	Positive/negative
Anticoagulant therapy	Yes/no
Lymph node swelling	Yes/no
Previous injections	Yes/no
Diffuse	
Fulminant sepsis	
Localized	
Hematoma from injection	
Puncture of a larger vessel during injection <sup>43</sup>	

**Table 4** Differential diagnostic evaluations of ulcerations that may be related to filler injections

Ulceration	
Local infection	Yes/no
Lymph node swelling	Yes/no
Previous injections	Yes/no
Constitutional symptoms	Yes/no
Diffuse	
Multiple ulcerating infiltrates/tumors	
Localized	
Intravascular injection	
Pyoderma gangrenosum	
Atypical mycobacteriosis	


**Table 3** Differential diagnostic evaluations of facial necroses that may be related to filler injections


Facial necroses	
Family history	Positive/negative
Medication	Yes/no
Lymph node swelling	Yes/no
Previous injections	Yes/no
Diffuse	
Necrotizing fasciitis <sup>44</sup>	
Localized	
Inadvertent intravascular filler injection	
High tissue pressure from injected material and/or swelling	

## Treatment Options

The selection of an appropriate treatment regimen in filler-induced adverse events depends on filler material, clinical onset of complications, the duration of granulomas, localization, and degree (→Table 5). For instance, it makes a big difference whether a swelling and induration occurs one day after treatment with pure hyaluronic acid or a few months after polymethyl methacrylate injection.

Among the most serious adverse effects are prolonged blanching followed by painful vascular compromise, necrosis<sup>13</sup> or ulceration, blindness<sup>14</sup> due to vascular injection in the glabella and granuloma tissue formation.<sup>15</sup> Using blunt cannulas for injections instead of sharp needles markedly reduce the risk for intravascular injections and vascular compromises,<sup>16</sup> avoidance of the use of more than one filler at the same time and the same injection site in general diminishes the complication rate. Unpleasing aesthetic results belong, strictly speaking, not to filler complications, but should be treated similarly. In the vast majority of cases, they are due to asymmetric augmentation or overfilling with hyaluronic acid. Because of its hygroscopic

**Fig. 1** Assessment of the distribution of hyaluronic acid after lip (A) and cheek augmentation (B, C) using magnetic resonance imaging with fat-suppression technique.



**Fig. 2** Varieties of histopathological findings in filler granulomas. (A) Granuloma after Dermalive injection showing giant cells and lymphatic infiltration. (B) Granuloma due to poly-L-lactic acid presenting multi-nuclear giant cells and needle-like birefringent structures. HE staining,  $\times 400$ .

chemical features, an apparently good result immediately after injection may change towards a mediocre outcome on the following day. Particularly, the periorbital area with loose connective tissue is prone to develop swelling and edema exposing visible overcorrection (**►Fig. 3**).

Local injection with hyaluronidase (Hyalase [Riemser Pharma, Greifswald, Germany]), the antidote of hyaluronic acid, will effectively solve this problem.<sup>17–19</sup> The solution for injection contains 75 U/0.5 mL NaCl added to 1.5 mL lidocaine, supplemented with 1% adrenaline. In general, 5 to 50 U of hyaluronidase are used per nodule. Response to injection can be expected within 24 to 72 hours, reinjection after 1 week is possible.

To quickly and most effectively treat severe early adverse effects such as vascular compromise physicians should be



**Fig. 3** Overtreatment with volumizing hyaluronic acid. Photo taken 1 day after the treatment.

trained in early detection and medical handling. Agents such as nitro paste or hyaluronidase (**►Fig. 4**) and cool or warming pads should be ready to handle.

The treatment modalities of granulomas are different. They require great experience and proper selection of a treatment regimen out of many possibilities (**►Table 6**). Interdisciplinary planning and profound knowledge of the pharmacology of eligible agents are basic conditions for a successful outcome. The first-line therapy of granulomas is based on the intralesional injection of crystalline steroids, even despite the risk of skin atrophy. Topical immunomodulating agents and immune response modifiers such as imiquimod (Aldara, Zyclara), 0.1% tacrolimus ointment (Protopic), and pimecrolimus cream (Elidel) are best suited for initial therapy of superficial granulomatous inflammation (**►Fig. 5**).

In cases resistant to steroidal and immunomodulatory treatment, mostly side effects of permanent fillers, intralesional 5-fluorouracil (5-FU) injections can be considered<sup>15,19</sup> (**►Fig. 6**). A possible solution for injection contains 0.8 mL 5-FU 250 mg/mL added by 0.1 mL triamcinolone 10 mg/mL and 0.1 mL of 1% scandicaine. In patients with permanent recalcitrant filler granuloma, this treatment may be combined with the oral administration of allopurinol.<sup>20</sup> Initially 200 mg/d is given in the first 2 weeks, followed by an increase to 400 mg/d in week 3, and a further increase to 600 mg per day from week 4 as maintenance dose. This treatment extends several months, depending on the clinical course. It may be flanked by systemic corticosteroids in acute inflamed granulomas as well as antibiotics if superinfection is suspected clinically.

Surgical excision of granuloma tissue formation is an option of last resort, if all other conservative treatment options fail. Dangerous filler migration, tumor growth, and increasing aesthetic compromise are some indications (**►Fig. 7A**). Due to the finger-like growth pattern of the diffusely distributed filler substances, the recurrence rate is high and complete removal cannot be achieved in most cases.



**Table 5** General treatment recommendations in filler side effects

Clinical symptom	Therapeutic strategy
Physiological reactions such as swelling, sensation of pressure	Cooling, nonsteroidal antiphlogistics
Overtreatment of hyaluronic acid (HA)	Hyaluronidase (Hyalase) = antidote of HA
Asymmetry	Touch-up filler injection, in case of HA localized hyaluronidase injection
Vascular compromise	Nitro paste, acetylsalicylic acid, heparin-infusion, warming, hyaluronidase after HA
Necrosis, ulcerations	Sterile, antiseptic wound treatment, surgical debridement
Hematoma	Heparin ointment
Discoloration	Bluish discoloration due to vessel dilatation: intense pulsed light (IPL), laser
Nodules	Puncture to distinguish sterile from bacterial abscess
	Sterile abscess: intralesional corticosteroids (cave atrophy), excision of superficial nodules resistant to topical therapy
	Suppurative abscess: antibiotics, incision
Hypertrophic scar at injection site	Intralesional steroid, dermabrasion
Granuloma	Anti-inflammatory and/or immunomodulatory therapy, surgical removal
All kinds of side effects	Compelling information on treatment, medicolegal aspects, and payment Good psychological support

Beside all therapeutic efforts, proper patient selection may prevent from later calamities. Patients suffering from acute systemic infections or skin infections at injection sites, known allergies to injection materials or egg white,

severe autoinflammatory disorders, and major cardiac dysfunction should not be treated, neither those reporting multiple intolerance reactions.<sup>21,22</sup> If allergic reactions are suspected clinically, skin testing has to be considered



**Fig. 4** Vascular compromise due to injection of hyaluronic acid with a sharp 27 G needle. After development of a painful blanching, the concerned area of facial artery and vein was injected by Hylase Dessau 150 U/mL NaCl and also superficially treated with the vasodilative nitro paste. Pain and swelling quickly decreased, but on day 1 after treatment (A) the patient presented with a dusky red discoloration, with significant relief on day 3 (B), day 7 (C), and day 14 (D). White area shown in (B) resulted from the removal of makeup.

**Table 6** Therapy options in filler-induced granulomas

Hyaluronidase for treatment of hyaluronidase injection-induced granuloma	Solution for injection: 75 U/0.5 mL NaCl + 1.5 mL lidocaine supplemented with 1% adrenaline Use 5–50 U hyaluronidase per nodule Response to injection can be expected within 24–72 h, reinjection after 1 week possible
Topical immunomodulating agents and immune response modifiers (imiquimod: Aldara, Zyclara; tacrolimus: 0.1% Protopic ointment; pimecrolimus: Elidel cream) for superficial granulomatous inflammation	Treatment twice daily for a minimum of 14 d Treatment duration up to several months in case of good response
Intralesional triamcinolone (10 mg/mL) in bigger nodules caused by degradable or permanent fillers	Initially, 0.1 mL per granuloma in weekly intervals (up to 4 wk) In case of good response, injections should be performed monthly for 3–6 mo (cave of skin atrophy)
Intralesional 5-fluoruracil (5-FU) injections for granuloma due to permanent fillers (Dermalive, and so on) (Protective eyewear during injection procedure)	Solution for injection: 0.8 mL 5-FU 250 mg/mL + 0.1 mL triamcinolone 10 mg/mL, supplemented with 0.1 mL scandicaine 1% At maximum 1–1.5 mL each session Therapy at weekly intervals initially, intervals can be expanded in the course of treatment Duration of treatment: months to years
Oral allopurinol for permanent filler granuloma, where applicable combined with 5-FU injections	200 mg/d in the first 2 wk, increase to 400 mg/d in wk 3, and further to 600 mg/d from wk 4 as maintenance dose Duration of treatment: months
Systemic corticosteroids in acute inflamed granuloma, for example, after polylactic acid (Sculptra)	Prednisolone 20–80 mg/d, adjusted to body weight Duration and tapering: up to 4 wk depending on the clinical course
Surgical excision as final treatment option	
Oral antibiotics if superinfection is suspected clinically	Cefuroxime 500 mg twice a day

**Fig. 5** Granulomatous inflammation due to permanent makeup (A). Good remission after local immunomodulatory treatment with pimecrolimus cream (Elidel) for 2 weeks, twice daily (B).

in advance.<sup>23,24</sup> To keep the risk of a filler side effect as low as possible patients are advised to refrain from extensive sun exposure, sauna, and substantial physical exertion.


Not to be forgotten in the context of filler complications are medicolegal aspects. Patients must be informed about all possible complications and informed consent must be obtained before injection. Also, they should be advised that all costs of treatment have to be covered at their own expense, since aesthetic procedures and their complications are non-insured medical events.

A good psychological support from the very beginning of the onset of a filler side effect is just as important as medical care. It is of paramount importance to provide the patient with all necessary information. This should be best done in a reassuring but concise way in an empathetic and professional atmosphere.

Whenever signs of psychological decompensation first appear the indication of immediate psychiatric treatment should be considered.

## Conclusion

The use of injectable fillers in aesthetic medicine is safe if applied professionally according to the principles of good clinical practice. Before injection, patients should be comprehensively informed about the actual procedures.




**Fig. 6** Successful treatment of a patient suffering from therapy-resistant granulomas after Dermalive injections (hydroxy-ethyl-methacrylate, ethyl-methacrylate, hyaluronic acid) into the nasolabial fold 7 years after injection. Clinical view before (A) and 6 months after therapy (B) with 5-fluorouracil (5-FU). Intralesional injections of 1 to 1.5 mL of 5-FU 250 mg/0.8 mL, supplemented with triamcinolone acetonide 0.1 mL and scandicaine 1% 0.1 mL, according to the treatment scheme of Table 6. Sonographic checks before (C), after 7 months (D), and 9 months (E) show significant reduction of granuloma formation. Biopsy taken before treatment shows foreign-body giant cells (arrows), macrophages, and lymphatic infiltration (F).

Filler-related adverse events should be part of the informed consent, specifically, granulomas, papules, nodules, subcutaneous swelling, bruising, necrosis, and ulceration. If these side effects are recognized early prompt therapy should be initiated, based on the clinical

symptoms and the injected materials. Proper handling can help to improve the clinical outcome and mitigate disappointment. Hyaluronic acid-products have found to be the safest fillers and the only ones with a real antidote.





**Fig. 7** Therapy-resistant suppurative granuloma in the glabella area with tendency to migrate into the upper lid. (A) Clinical view before surgery, (B) dissection, (C) situs after tumor excision, (D) tailoring of the defect, (E) closure of the defect after wide undermining of the adjacent tissue by stretch plasty, (F) complete closure, (G) aesthetically pleasing result with scars running along relaxed skin tension lines. (Image courtesy of Werner J. Heppt).

## References

- van der Meer WJ, Dijkstra PU, Visser A, Vissink A, Ren Y. Reliability and validity of measurements of facial swelling with a stereophotogrammetry optical three-dimensional scanner. *Br J Oral Maxillofac Surg* 2014;52:922–927
- Sabet-Peyman EJ, Woodward JA. Complications using intense ultrasound therapy to treat deep dermal facial skin and subcutaneous tissues. *Dermatol Surg* 2014;40(10):1108–1112
- Hirsch RJ, Lupo M, Cohen JL, Duffy D. Delayed presentation of impending necrosis following soft tissue augmentation with hyaluronic acid and successful management with hyaluronidase. *J Drugs Dermatol* 2007;6(3):325–328
- Brody HJ. Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement. *Dermatol Surg* 2005;31(8, Pt 1):893–897
- Soparkar CN, Patrinely JR. Managing inflammatory reaction to restylane. *Ophthalm Plast Reconstr Surg* 2005;21(2):151–153
- Ginat DT, Schatz CJ. Imaging features of midface injectable fillers and associated complications. *AJNR Am J Neuroradiol* 2013;34(8):1488–1495
- Grippaudo FR, Di Girolamo M, Mattei M, Pucci E, Grippaudo C. Diagnosis and management of dermal filler complications in the perioral region. *J Cosmet Laser Ther* 2014;16(5):246–252
- Grippaudo FR, Pacilio M, Di Girolamo M, Dierckx RA, Signore A. Radiolabelled white blood cell scintigraphy in the work-up of dermal filler complications. *Eur J Nucl Med Mol Imaging* 2013;40(3):418–425
- Park TH. Comment on Grippaudo et al. Radiolabelled white blood cell scintigraphy in the work-up of dermal filler complications. *Eur J Nucl Med Mol Imaging* 2013;40(5):790–791
- Persichetti P, Palazzolo D, Tenna S, Poccia I, Abbruzzese F, Trombetta M. Dermal filler complications from unknown biomaterials: identification by attenuated total reflectance spectroscopy. *Plast Reconstr Surg* 2013;131(4):597e–603e
- Malik S, Mehta P, Adesanya O, Ahluwalia HS. Migrated periocular filler masquerading as arteriovenous malformation: a diagnostic and therapeutic dilemma. *Ophthalm Plast Reconstr Surg* 2013;29(1):e18–e20
- Kadouch JA, Tutein Nolthenius CJ, Kadouch DJ, van der Woude HJ, Karim RB, Hoekzema R. Complications after facial injections with permanent fillers: important limitations and considerations of MRI evaluation. *Aesthet Surg J* 2014;34(6):913–923
- Narins RS, Jewell M, Rubin M, Cohen J, Strobos J. Clinical conference: management of rare events following dermal fillers—focal necrosis and angry red bumps. *Dermatol Surg* 2006;32(3):426–434
- Lazzeri D, Agostini T, Figus M, Nardi M, Pantaloni M, Lazzeri S. Blindness following cosmetic injections of the face. *Plast Reconstr Surg* 2012;129(4):995–1012
- Wiest LG, Stolz W, Schroeder JA. Electron microscopic documentation of late changes in permanent fillers and clinical management of granulomas in affected patients. *Dermatol Surg* 2009;35(Suppl 2):1681–1688



- 16 Fulton J, Caperton C, Weinkle S, Dewandre L. Filler injections with the blunt-tip microcannula. *J Drugs Dermatol* 2012;11(9):1098–1103
- 17 Lemperle G, Rullan PP, Gauthier-Hazan N. Avoiding and treating dermal filler complications. *Plast Reconstr Surg* 2006;118(3, Suppl):92S–107S
- 18 Lemperle G, Duffy DM. Treatment options for dermal filler complications. *Aesthet Surg J* 2006;26(3):356–364
- 19 Sclafani AP, Fagien S. Treatment of injectable soft tissue filler complications. *Dermatol Surg* 2009;35(Suppl 2):1672–1680
- 20 Reisberger EM, Landthaler M, Wiest L, Schröder J, Stolz W. Foreign body granulomas caused by polymethylmethacrylate microspheres: successful treatment with allopurinol. *Arch Dermatol* 2003;139(1):17–20
- 21 Narins RS, Coleman WP III, Glogau RG. Recommendations and treatment options for nodules and other filler complications. *Dermatol Surg* 2009;35(Suppl 2):1667–1671
- 22 Funt D, Pavicic T. Dermal fillers in aesthetics: an overview of adverse events and treatment approaches. *Clin Cosmet Investig Dermatol* 2013;6:295–316
- 23 Alijotas-Reig J, Fernández-Figueras MT, Puig L. Inflammatory, immune-mediated adverse reactions related to soft tissue dermal fillers. *Semin Arthritis Rheum* 2013;43(2):241–258
- 24 Alijotas-Reig J, Fernández-Figueras MT, Puig L. Late-onset inflammatory adverse reactions related to soft tissue filler injections. *Clin Rev Allergy Immunol* 2013;45(1):97–108
- 25 Téllez Villajos L, Rodríguez de Santiago E, Aicart Ramos M, Cuño Roldán JL, Moreira Vicente V, Albillos Martínez A. Elevation of pancreatic enzymes and facial edema. DRESS syndrome [in Spanish]. *Gastroenterol Hepatol* 2014; [E-pub ahead of print]
- 26 Chan NJ, Soliman AM. Angiotensin converting enzyme inhibitor-related angioedema: onset, presentation, and management. *Ann Otol Rhinol Laryngol* 2014; [E-pub ahead of print]
- 27 Choi HJ. Pseudocyst of the neck after facial augmentation with liquid silicone injection. *J Craniofac Surg* 2014;25(5):e474–e475
- 28 Gakhal MS, Marcotte GV. Hereditary angioedema: imaging manifestations and clinical management. *Emerg Radiol* 2014
- 29 Yoshida N, Kaieda S, Yoshimura S, Ida H. Facial and laryngeal edema in a patient with dermatomyositis. *Intern Med* 2014;53(8):921
- 30 Olazagasti J, Lynch P, Fazel N. The great mimickers of rosacea. *Cutis* 2014;94(1):39–45
- 31 Yelnoorkar S, Issing W. Cervicofacial surgical emphysema following tonsillectomy. *Case Rep Otolaryngol* 2014;2014:746152
- 32 Vleggaar D, Fitzgerald R, Lorenc ZP. Understanding, avoiding, and treating potential adverse events following the use of injectable poly-L-lactic acid for facial and nonfacial volumization. *J Drugs Dermatol* 2014;13(4, Suppl):s35–s39
- 33 Zhu S, Pyatkevich Y. Ramsay Hunt syndrome type II. *Neurology* 2014;82(18):1664
- 34 Motamedi MH, Behroozian A, Azizi T, Nazhvani AD, Motahary P, Lotfi A. Assessment of 120 maxillofacial aneurysmal bone cysts: a nationwide quest to understand this enigma. *J Oral Maxillofac Surg* 2014;72(8):1523–1530
- 35 Chi TH, Chen HS, Yuan CH, Tsao YH. Deep lobe parotid abscess with facial nerve palsy: a case report. *West Indian Med J* 2013;62(9):856–858
- 36 Requena C, Requena L, Alegre V, et al. Adverse reaction to silicone simulating orofacial granulomatosis. *J Eur Acad Dermatol Venereol* 2014; [E-pub ahead of print]
- 37 Feng S, Yin J, Li J, Song Z, Zhao G. Melkersson-Rosenthal syndrome: a retrospective study of 44 patients. *Acta Otolaryngol* 2014;134(9):977–981
- 38 Assouan C, Anzouan K, Nguessan ND, et al. Tuberculosis of the temporomandibular joint. *Rev Stomatol Chir Maxillofac Chir Orale* 2014;115(2):88–93
- 39 Quach KA, Zaenglein AL. The eyelid sign: a clue to bed bug bites. *Pediatr Dermatol* 2014;31(3):353–355
- 40 Bassetti M, Bassetti R, Sculean A, Salvi GE. Subcutaneous emphysema following non-surgical peri-implantitis therapy using an air abrasive device: a case report [in German]. *Swiss Dent J* 2014;124(7-8):807–817
- 41 Lim JL. Periorbital oedema after dental extraction: a case study. *Aust Fam Physician* 2014;43(8):543–544
- 42 Maralani P, Mohan S, Rassekh CH, Loevner LA. Salivary neoplasms presenting with radiologic venous invasion: an imaging pearl to diagnosing metastatic renal cell carcinoma. *ORL J Otorhinolaryngol Relat Spec* 2014;76(2):105–109
- 43 Ribeiro AL, Silva WB, Menezes SA, Kataoka MS, Alves SM Jr, Pinheiro JJ. Life-threatening expansive sublingual hematoma: a stab wound with lingual artery injury. *J Craniofac Surg* 2014;25(1):e61–e65
- 44 Stone LA, Harshbarger RJ III. Orbital necrotizing fasciitis and osteomyelitis caused by *Arcanobacterium haemolyticum*: a case report. *Ophthal Plast Reconstr Surg* 2014; [E-pub ahead of print]